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Objectives
Poly-L-lactic acid (PLA) injections modestly increase objectively assessed facial thickness but not
facial soft tissue volume (FSTV) over 24 weeks. The durability of this response has not been well
deﬁned objectively.
Methods
HIV-infected lipoatrophic adults were randomized to four open-label PLA treatments administered
every 2 weeks from week 0 (immediate group, n550) or from week 24 (deferred group, n550).
Endpoints included FSTV assessed by computed tomography, facial lipoatrophy severity, quality of
life (QoL) and safety. Analyses were by intention to treat.
Results
Between weeks 24 and 48, soft tissue thickness increased modestly in injection planes, at the
maxillary [mean 0.9mm; 95% conﬁdence interval (CI) 0.3–1.5mm; P50.007] and base of nasal
septum levels (mean 0.4mm; 95% CI 0.1–0.8; P50.021), but not in untreated areas (P50.79 and
P50.24). PLA durability assessed at week 48 in immediate group participants showed a mean
change in FSTV of 14cm
3 (95% CI 1t o2 9c m
3; P50.060) and increased tissue depth at the
maxillary (Po0.0001), base of nasal septum (Po0.0001) and mandibular (P50.0035) levels. At
week 48, clinicians and patients subjectively assessed facial lipoatrophy severity as reduced in
immediate participants (83 and 91%, respectively), and the Mental Health scale score of the Short
Form-36 Health Survey improved signiﬁcantly in immediate participants relative to deferred
participants (P50.027). Subcutaneous injection-site nodule incidence at 48 weeks was 10%.
Conclusions
PLA treatment beneﬁts were durable, with objectively assessed modest increases in facial volume
and tissue thickness sustained over 48 weeks in injection planes but not in other facial areas.
Improvements in some QoL domains were maintained.
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Introduction
Lipoatrophy of subcutaneous adipose tissue in the limbs,
face and buttocks, and accumulation of adipose tissue in
the intra-abdominal space, dorsocervical region and the
breasts are major features of HIV lipodystrophy [1,2].
Facial lipoatrophy, the most distressing manifestation, can
be stigmatizing, severely affecting quality of life (QoL) and
self-esteem, and may result in reduced antiretroviral (ARV)
adherence [3]. Although use of the newer nonthymidine
nucleoside reverse transcriptase inhibitors is associated
with less lipoatrophy [4], in the absence of proven
therapies, management of established fat loss can be
challenging as reversal is slow [5–7].
An array of injectable ﬁlling agents has been marketed
for soft tissue augmentation and many of these are used
for aesthetic management of HIV facial lipoatrophy [8].
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163Poly-L-lactic acid (PLA; Sculptrat; Dermik Laboratories,
Bridgewater, NJ, USA), a synthetic, biodegradable, im-
munologically inert, resorbable polymer, approved in
Europe and the USA for use in HIV facial lipoatrophy, is
used most commonly. Although open-label studies have
demonstrated PLA safety in HIV-infected adults [9–18],
PLA efﬁcacy has been objectively assessed in only one
randomized clinical trial [19]. This open-label, multicentre
study compared immediate vs. deferred PLA injections in
adults with moderate to severe facial lipoatrophy. The
study’s primary objective was to determine the effect of
four bilateral PLA treatments administered every 2 weeks
on facial soft tissue volume (FSTV) over 24 weeks using
volumetric computed tomography (CT). At 24 weeks,
although PLA had not increased FSTV, signiﬁcant but
clinically modest improvements in objectively assessed
tissue thickness at the planes of injection were demon-
strated. We report here longer term efﬁcacy, safety and
durability.
Methods
Participants
Details of participants’ eligibility, randomization and
baseline characteristics have been reported previously in
the 24-week primary efﬁcacy comparison [19].
All participants provided written, informed consent
following approval by the local human research ethics
committee at each site.
Interventions
At baseline, 100 eligible patients were randomized to
receive four open-label PLA treatments [one vial (150mg)
per cheek] every 2 weeks with a minimum 14-day interval
between treatments commencing either at week 0 (im-
mediate group; n550) or following a delay period of 24
weeks (deferred group; n550). At weeks 0, 2, 4 and 6,
immediate group participants received bilateral PLA
injections at a single surgical location in each of the four
participating Australian states according to a common
protocol [19]. Following completion of the 24-week study
visit, the deferred group also received four bilateral PLA
injections at weeks 25, 27, 29 and 31 at the four surgical
locations protocoled. Management guidelines for PLA-
related adverse events included treatment delay or
termination. PLA cessation was mandatory for grade 4
(very severe or life-threatening) events considered deﬁ-
nitely, probably or possibly related to PLA. Antiretroviral
therapy (ART) changes were permitted for on-study adverse
events or virological failure.
Assessments
Assessments performed to week 24 have been published
previously [19]. All participants were seen at weeks 36 and
48. Additionally, deferred group participants were seen at
weeks 26, 28, 30 and 32 for a post-procedure and safety
review. Safety assessments included physical examination,
recording of clinical adverse events and concomitant drugs
and measurements of plasma HIV-1 RNA and T-lympho-
cyte subsets. Women of child-bearing potential in the
deferred group had serum b-human chorionic gonadotro-
phin testing immediately prior to PLA commencement. At
week 48, spiral CT of the head was performed with
subsequent volumetric assessment using three-dimensional
(3D) post-processing software to quantify total FSTV of the
region deﬁned superiorly by the mid-orbit and inferiorly
by the angle of the mandible [19]. Four protocol-deﬁned
bony landmarks were identiﬁed on four axial images and
with the measurement tool baselines were drawn at the
level of the mandible, the base of the nasal septum, the
maxilla and the orbit. From each baseline the maximum
distance to the skin line was recorded as
the mandible, base of nasal septum, maxilla and orbit
measurements, respectively. Other objective body composi-
tion measures collected at each visit were weight, body
mass index (BMI), and hip and waist circumferences.
Subjective measures of lipodystrophy severity were re-
corded independently by clinicians and patients at each
time-point. Each body region was scored according to a
standardized system (0 for none, 1 for mild, 2 for moderate
or 3 for severe) [20,21].
Health-related QoL was self-reported using the Short
Form (SF)-36v2 Health Survey at weeks 36 and 48 [22].
Self-satisfaction with appearance and weight was assessed
using the Multidimensional Body-Self Relations Question-
naire-Appearance Scales (MBSRQ-AS), a standardized
measure of body image attitudes [23]. ARV adherence
was assessed using a standardized self-report form [24].
Participants recorded whether they took ‘all’, ‘most’, ‘about
half’, ‘very few’, or ‘none’ of their medication during the
preceding 7 days.
Statistical analysis
When the week 24 primary efﬁcacy analysis did not
demonstrate a signiﬁcant change in FSTV, the Protocol
Steering Committee requested that an interim analysis be
performed on all data to week 48 to evaluate PLA
durability, safety and tolerability. Moreover, if there was
no signiﬁcant change in FSTV, the study should be
terminated. An analysis plan was ﬁnalized prior to
database closure. The week 48 statistical analysis was
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pleted at least 48 weeks of follow-up, or had permanently
withdrawn from follow-up. Changes from baseline in
efﬁcacy endpoints were summarized at each study visit.
Time windows were deﬁned by the mid-point between
nominal study weeks, except for facial CT scans which were
performed within 4 weeks of week 48; if more than one
measurement of a parameter were available in a time
window, the mean value was used. Efﬁcacy analyses
compared the randomized treatment groups on an inten-
tion-to-treat basis in terms of change from baseline to
week 48 and included all participants with baseline data
and at least one follow-up assessment. A last-value-
carried-forward approach was utilized for participants lost
to follow-up. Secondary analyses used only available data.
Continuous endpoints were investigated using analysis of
variance or nonparametric equivalents and binary end-
points were assessed by w
2 tests or logistic regression. All
signiﬁcance tests were two-sided and not adjusted for
multiple comparisons.
PLA durability at week 48, as measured by CT, was
assessed in the immediate group only. A pooled analysis
based on available data assessed change from baseline to
24 weeks post-treatment in FSTV and facial linear
measurements. Baseline data for the deferred group were
week 24 data (immediately prior to PLA start).
Serious adverse events, adverse events associated with
PLA or leading to changes in ART, and all grade 3 or
4 clinical adverse events were summarized at each study
visit by treatment group. Events associated with PLA
modiﬁcation or cessation were summarized. An ARV
adherence score was calculated as described previously
[24]. Subgroup analyses were based on the following
strata: age, patient-assessed facial lipoatrophy severity,
baseline protease inhibitor (PI) and thymidine nucleoside
reverse transcriptase inhibitor (NRTI) use, and surgeon.
Differences in outcome between randomized treatment
arms were assessed with tests of interaction between
treatment and strata.
Univariate and multivariate linear regressions were used
to determine predictors of PLA efﬁcacy, deﬁned on the
basis of a change in FSTV greater than the pooled median
change 24 weeks after PLA initiation, and predictors of an
increase in linear measurements (base of nasal septum and
maxillary levels) 24 weeks after PLA initiation. The
following variables were assessed as predictors: baseline
demographic characteristics, ARV treatment, CD4 cell
count and HIV-1 viral load, smoking status, skin tanning
type (Fitzpatrick scale) [25], treatment group (immediate/
deferred), baseline FSTV, baseline and week 24 limb fat
mass and percentage, and change in limb fat mass and
percentage at week 24 assessed by dual-energy X-ray
absorptiometry (DEXA). Baseline characteristics for de-
ferred participants were week 24 data, except for body
composition data where week 0 and week 24 were utilized
as no week 48 DEXA was protocoled. Multivariate models
considered all variables with a P-value  0.1 in initial
analyses, and used forward stepwise methods. All analyses
were performed using STATA Statistical Software version 10
(Stata Corporation, College Station, TX, USA).
Results
One hundred participants (50 immediate; 50 deferred)
contributed to the week 24 randomized comparison.
Subsequently, three participants (two immediate and one
deferred) withdrew consent (patient choice), and one
(immediate) was lost to follow-up (Fig. 1). Most (92%)
participants were men, 35% had AIDS, and all were
receiving ART: 65 were receiving a PI-based regimen
and 14 a thymidine NRTI. Mean   standard deviation (SD)
baseline FSTV was 388   71 cm
3 in the immediate group
and 393   69cm
3 in the deferred group [19].
Forty-eight of the 49 deferred participants (98%)
received four bilateral PLA treatments. One participant
required only three treatments (six vials) for adequate
facial correction. Twenty-ﬁve ARV drugs were stopped in
16 participants (16%; 10 immediate and six deferred). Six
agents were discontinued for virological failure (two
immediate participants), seven for toxicity (six partici-
pants; four immediate and two deferred), and the remain-
ing 12 (48%) for regimen simpliﬁcation. The drugs
discontinued most commonly were lamivudine (seven
participants; four immediate and three deferred), lopinavir/
ritonavir (four immediate) and tenofovir (three immediate).
Thymidine NRTI therapy was stopped in two participants
(one immediate and one deferred), and no participant
ceased PI therapy. No participant received any additional
intervention or procedure for lipodystrophy. There was no
death, new AIDS-deﬁning event, or protocol violation.
Data for 100 participants (50 immediate and 50 deferred)
were available for the intention-to-treat analysis.
Efﬁcacy: objective measures
Between weeks 24 and 48, tissue thickness in injection
planes, at base of nasal septum and maxillary levels,
increased signiﬁcantly [mean 0.4mm; 95% conﬁdence
interval (CI) 0.1–0.8mm; P50.021 and mean 0.9mm; 95%
CI 0.3–1.5mm; P50.007, respectively] in immediate group
participants, but there was no change at the untreated
orbital and mandibular levels (Table 1 and Fig. 2). PLA
durability, assessed in immediate group participants at 48
weeks, showed a mean change in FSTV of 14cm
3 (95% CI
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3; P50.060; Table 1) and increased tissue
depth at maxillary, base of nasal septum and mandibular
levels (Table 1).
Pooled 24-week analysis using available data (n596)
demonstrated a signiﬁcant mean change from baseline in
FSTV (15cm
3; 95% CI 5–24cm
3). PLA increased tissue
thickness at the maxilla and base of nasal septum levels
(mean 1.2mm; 95% CI 0.8–1.5 and 2.5mm; 95% CI 2.1–
2.9mm, respectively), but there was no change in thickness
at the untreated orbit and mandibular levels (mean 0.8mm;
95% CI 0–1.5 and  0.3mm; 95% CI  0.9 to 0.3mm,
respectively). Analyses to investigate predictors of a good
24-week volumetric response to PLA, deﬁned as an FSTV
change greater than the overall pooled median change
(12.6cm
3) 24 weeks post-treatment, produced inconsistent
data. In multivariate analysis, independent predictors of a
volumetric response (412.6cm
3) were deferred treatment
group (P50.002), and a baseline FSTV above the median
(P50.031). Predictors of a greater increase in tissue
thickness at the maxillary level were surgical site
(P50.009), and Fitzpatrick skin types IV–VI (P50.001).
There were no signiﬁcant predictors of a tissue thickness
increase at the base of nasal septum level.
A 24-week treatment delay did not impact PLA efﬁcacy.
At week 48, the mean change in FSTV was 14cm
3 (95%
CI  1t o2 9 c m
3) in the immediate group and 18cm
3
(95% CI 5–30cm
3) in the deferred group, a between-group
difference of  4cm
3 (95% CI  22 to 16cm
3; P50.71;
Fig. 3). These represent changes in FSTV of 4 and 5%,
respectively (between group difference  1%; P50.66).
There was no between-group difference in mean change in
tissue depth in injection planes (maxilla, P50.22; base of
nasal septum, P50.44; Fig. 2). Tissue thickness at the
untreated orbital and mandibular levels did not differ
(P50.11 and P50.40, respectively) (Fig. 2). Treatment
efﬁcacy, assessed by change in FSTV at week 48, did not
Table 1 Change in objective facial measures in immediate participants
Baseline (n550)
Change between weeks 24 and 48 (n547)* Week 48 change from baseline (n550)
w
Mean (SD) Mean (%) 95% CI P Mean (%) 95% CI P
Facial soft tissue volume (cm
3) 388 (71) 14 (4)  1 to 29 0.060 14 (4)  1 to 29 0.060
Linear measurements (mm)
z
Mandible 21 (5) 0.4 (2)  0.3 to 1.3 0.24 1.0 (4) 0.3–1.6 0.0035
Base of nasal septum 28 (4) 0.4 (2) 0.1–0.8 0.021 1.7 (6) 1.1–2.2 o0.0001
Maxilla 12 (3) 0.9 (8) 0.3–1.5 0.007 3.1 (27) 2.4–3.8 o0.0001
Orbit 13 (3) 0.1 (1)  0.4 to 0.5 0.79 0.1 (1)  0.4 to 0.7 0.59
*Includes all subjects with week 24 data (intention to treat).
wIncludes all subjects with week 0 data (intention to treat).
zMean of left- and right-sided measurements.
CI, conﬁdence interval; SD, standard deviation.
Randomized
n=101
1 lost to follow-up
2 withdrew (pt choice)
DEFERRED PLA
n=50
IMMEDIATE PLA
n=51
1 withdrew
(pt choice)
1 withdrew
(pt choice)
Received PLA week 0
n=50
Analysed week 24
n=50
Analysed week 24 
n=50
Week 48: Analysis populations
ITT=50
OT=47
Week 48: Analysis populations
ITT=50
OT=47
Received PLA week 25
n=49
Fig. 1 Patient follow-up.
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shown). At week 48, there was no between-group
difference in plasma viral load (P50.40), CD4 lymphocyte
counts (P50.53), self-reported ARV adherence (P50.75),
or any objective body composition measure [weight
(P50.81), BMI (P50.91), waist circumference (P50.72),
or waist-to-hip ratio (P50.40)].
Efﬁcacy: subjective measures
At week 48, patients and clinicians perceived sustained
improvements in facial lipoatrophy severity in immediate
participants, with 83 and 91%, respectively, assessing
severity as reduced (Fig. 4). There was no difference in
any other clinician- or patient-assessed subjective measure
of lipodystrophy or its severity at week 48 in immediate
participants. In the deferred group, facial lipoatrophy
severity was assessed as reduced by 82% of deferred PLA
recipients and 88% of clinicians at week 48 (Fig. 4). There
was no between-group difference in patient- or clinician-
assessed facial lipoatrophy severity at week 48 (P50.70
and 0.50, respectively) (Fig. 4), or any other clinician- or
patient-assessed subjective measure of lipodystrophy or its
severity.
At week 48, change from baseline in scores for Mental
Health and Social Functioning scales of the SF-36 Health
Survey in the immediate group were higher than those
observed at week 24 (data not shown). At week 48, the
mean change in the Mental Health score differed sig-
niﬁcantly in the immediate group relative to the deferred
group (5.2 and  3.7, respectively; P50.027). There was a
trend for a greater mean change in the score for Social
Functioning in the immediate group relative to the deferred
group (6.1 and  3.3, respectively; P50.078). There was
no between-group difference in the Physical Component
Summary score (P50.14), but there was a trend for
immediate group participants to have a greater increase in
the Mental Health Component Summary score (P50.072).
There was no between-group difference in any of the ﬁve
MBSRQ-AS-assessed body self-image subscale scores at
week 48.
Safety/tolerability
The majority (98%) of deferred participants experienced at
least one product/procedure-related adverse event, most
commonly pain/discomfort (73%), oedema (65%) and
erythema (49%). Adverse events were similar in frequency,
grade, onset time and duration to those reported by
immediate group participants [19]. At week 48, three
palpable and one visible subcutaneous noninﬂammatory
injection site nodules and one papule were ongoing in four
deferred participants (8%). At week 24, ﬁve injection site
subcutaneous noninﬂammatory nodules and one papule
had been ongoing in six immediate participants (12%).
Between weeks 24 and 48, one nodule and one papule
resolved spontaneously and one late-onset nodule and two
papules (three participants) were diagnosed. In total, 96 of
the 99 participants (97%) who received PLA experienced at
least one product/procedure-related adverse event (Table 2).
At week 48, eight nodules (seven palpable and one visible)
and two papules remained ongoing in 10 participants
(10%).
There were 10 serious adverse events in seven partici-
pants (three immediate and four deferred). No event was
associated with PLA, and no other grade 4 event was
considered to be deﬁnitely, probably or possibly related to
PLA.
Discussion
Following four bilateral PLA treatments in HIV-infected,
ARV-experienced adults with moderate or severe facial
lipoatrophy, clinically modest increases in objectively
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injection, but not facial volume, were demonstrated out to
week 48. Clinicians and patients perceived sustained
treatment beneﬁts with signiﬁcant improvements in facial
lipoatrophy severity assessed at week 48 in participants
treated at baseline. A 24-week treatment delay did not
impact change in FSTV or facial soft tissue thickness
compared with immediate treatment. Differences in some
QoL scores were observed. Subcutaneous nodule incidence
at 48 weeks was 10%.
Between weeks 24 and 48 there was a gradual but
signiﬁcant increase in tissue depth in two planes, the
maxilla and the base of the nasal septum, in early PLA
recipients. These increases can only be interpreted as a
durable PLA treatment beneﬁt as they were not accom-
panied by improvement in untreated facial areas. Gradual
increases in facial thickness are consistent with the
mechanism of action of PLA [26,27], which differs from
the more immediate beneﬁts achieved with the use of
nonbiodegradable ﬁlling agents such as polyacrylamide gel
[16] or polyalkylimide gel [28].
At week 48, mean tissue depth had increased to 3.1mm
at the maxillary level and 1.7mm at the base of the nasal
septum in early PLA recipients. These changes, while lower
than the week 48 changes reported in some studies
[9,11,17], are comparable to those reported in others
[13,14]. However, cross-study comparisons of PLA efﬁcacy
for HIV facial lipoatrophy are problematic because of the
heterogeneity of these studies. To date, all PLA studies have
been open-label, varying enormously in terms of the
number of treatments administered, study subjects, and
facial lipoatrophy severity and its assessment. Only one
earlier study utilized a validated lipodystrophy assessment
tool [29] to assess facial lipoatrophy severity [10]. PLA
studies lack objective lipodystrophy data. Validated mea-
sures of facial soft tissue thickness or volume for assessing
and/or comparing treatment efﬁcacy are also lacking.
Measurement methods employed have included ultrasono-
graphy [9,14,17], callipers [11], and 3D photography with
3D computerized reconstruction of the face [13], none of
which has been validated. Collectively, these factors
demonstrate the lack of scientiﬁcally valid data that relate
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Fig. 4 Percentage change in subjective facial lipoatrophy severity at week 48.
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Table 2 Overall procedure/product-related adverse events to week 48
Event
% Grades 1 & 2
(n5392)*
Median time to
onset (days)
Median duration
(days)
% Grades 3 & 4
(n5392)*
Median time to
onset (days)
Median duration
(days)
Pain/discomfort
w 73 0 2 4 0 2
Oedema
z 64 0 3 7 0 2
Erythema
z 50 0 2 4 0 2
Ecchymosis
z 9 0 3 1 0 6.5
Pruritus
z 80 2– ––
Inﬂammation
z 60 2– ––
Haematoma
z 10 5
Nodule (410mm) 7 1.5 76.5
§ –– –
Papule (o10mm) 4 4 7.5 – – –
*Based on total number of treatment procedures (immediate plus deferred groups).
wGrades 1 and 2, 1–5 on visual analogue scale; grades 3 and 4, 6–10 on visual analogue scale.
zGrades 1 and 2, o50mm; grades 3 and 4, 50–85mm.
§Eight nodule and two papule events were ongoing at week 48.
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broad inter-study variability in PLA treatment outcomes.
This is the ﬁrst study to use FSTV, an unbiased objective
measure, to assess treatment beneﬁts following soft tissue
augmentation. The increase in FSTV observed in deferred
participants 24 weeks after PLA initiation contrasts with
the lack of change observed at 24 weeks in participants
treated immediately. However, at week 48 FSTV had
increased in immediate PLA recipients and was not
different between groups. This disparity is probably
attributable to variability in the procedure and/or the
extent of the area of PLA injection relative to the facial
volume. Accurate measurement of facial volume necessi-
tated the single operator at each of the nine national
scanning sites to reconstruct the data sets at 24 and 48
weeks to mirror baseline image parameters. Failure to
adhere to this requirement could produce measurement
error. Additionally, the mid-orbit and the angle of the
mandible, which constituted the upper and lower land-
marks for FSTV, respectively, produced a volume substan-
tially greater than the area of PLA injection. As the
improvements in tissue thickness in injection planes were
modest, the resultant volumetric increases may have been
difﬁcult to detect, especially if the procedure was more
variable than expected.
The pooled 24-week analysis conﬁrmed a PLA treatment
beneﬁt with signiﬁcant but modest increases in facial
thickness around the planes of injection and in FSTV.
Between weeks 24 and 48, one participant in each arm
ceased stavudine therapy. Given the slow rate of lipoa-
trophy reversal following thymidine NRTI cessation
[30,31], we do not believe that this therapy change is
likely to have impacted study results. These data are
supported by no change in any objective body composition
parameter.
The objectively assessed increases in both FSTV and
facial soft tissue thickness were perceived by both patients
and clinicians, with most assessing improvements in
apparent facial lipoatrophy severity that were sustained
at week 48. Clinician- and patient-perceived facial
lipoatrophy severity did not differ between participants
treated at baseline and those treated after week 24.
Subjectively assessed lipodystrophy and its severity were
also assessed as not different, and this ﬁnding was
supported by no between-group difference in any objective
body composition measure.
Reliable and validated instruments measured the impact
of treatment on health-related QoL (SF-36) and body
self-image (MBSRQ-AS) [32]. Between weeks 24 and 48,
scores for Mental Health and Social Functioning scales
of the SF-36 continued to improve in participants who
received PLA at baseline, demonstrating ongoing patient-
perceived treatment beneﬁts. It is likely that these
improvements accounted for the differences in health-
related QoL outcomes observed at week 48, with improved
Mental Health and a trend towards increased Social
Functioning in the immediate group. In contrast, the
MBSRQ-AS assessment of psychological state showed that
scores for body-self image and self-satisfaction with
weight and appearance were not different between the
groups.
Safety data suggest that PLA injections are safe and well
tolerated over 48 weeks. Overall product/procedure-related
adverse events were transient and of low grade, compar-
able with those reported previously in this population
[9,13,33]. No severe or serious adverse event was associated
with PLA. While most subcutaneous noninﬂammatory
injection-site nodules resolved spontaneously during the
study, there were several late-onset nodules. Histological
examination of these nodules was not undertaken. At week
48, the incidence of injection site nodules was 10%,
although incidences ranging from 0 to 52% have been
reported in previous studies [9,11–16,18,33]. Incidences
were higher in early studies where PLA injection volumes
were 3–4mL [9,15,33]. Less concentrated solutions have
lower viscosity and so promote more even PLA dispersal
and reduced nodule formation [34], as demonstrated here
and in other recent studies [12,14,16]. Differences in
nodule incidence may also reﬂect differences in study
design. In the current study, clinicians actively sought and
palpated for nodules/papules, while others may have relied
solely on patient report. Nodule onset times were consistent
with those reported previously [13,35]; however, data on
nodule duration are incomplete as many remained ongoing
at study closure [9,13,17,33].
This study has its limitations. Most participants were
white men, a reﬂection of the Australian HIVepidemic. The
absence of a control group after week 24 means that we
cannot conﬁrm that the increases in facial soft tissue
thickness and volume were exclusively attributable to PLA
treatment and not to generalized improvements in
lipoatrophy per se. However, this is unlikely as tissue
thickness at the untreated orbit level, which did not
increase over the study period, served as a control. There is
no information describing normal FSTV in men, and hence
we are unable to assess to what extent facial volume
approached normality. However, overall our results suggest
that FSTV is not an ideal measure.
In conclusion, this multicentre, open-label study of PLA
treatment is the ﬁrst to demonstrate objectively assessed
clinically modest increases in facial volume and soft tissue
thickness that were sustained over 48 weeks in injection
planes but not in other facial areas. Patient-perceived
beneﬁts included aesthetic improvement and enhanced
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beneﬁts were greater in those treated at baseline. The cost
of soft tissue augmentation is substantial as third-party
providers contribute minimally. It is encouraging to know
that treatment delays, necessitated on ﬁnancial grounds,
would not be expected to impact outcomes adversely. The
optimal treatment approach for HIV facial lipoatrophy is
currently unknown. Research to deﬁne and compare the
most efﬁcacious ﬁlling agents for this distressing condition
will require use of validated diagnostic criteria and/or tools
to assess lipoatrophy severity and validated measures of
facial soft tissue thickness or volume.
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